tiprankstipranks
Gilead Sciences (IT:1GILD)
NASDAQ:1GILD
Italy Market
1GILD
Gilead Sciences
RESEARCH TOOLSreports

Gilead Sciences (1GILD) Stock Forecast & Price Target

3 Followers
See the Price Targets and Ratings of:

1GILD Analyst Ratings

Strong Buy
23Ratings
Strong Buy
19 Buy
4 Hold
0 Sell
Based on 23 analysts giving stock ratings to
Gilead
Sciences
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

1GILD Stock 12 Month Forecast

Average Price Target

€137.99
▲(20.62% Upside)
Based on 23 Wall Street analysts offering 12 month price targets for Gilead Sciences in the last 3 months. The average price target is €137.99 with a high forecast of €156.22 and a low forecast of €106.75. The average price target represents a 20.62% change from the last price of €114.40.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"92":"€92","157":"€157","108.25":"€108.3","124.5":"€124.5","140.75":"€140.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":156.2184036,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€156.22</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":137.99292318,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€137.99</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":106.74924245999999,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€106.75</span>\n  </div></div>","useHTML":true}}],"tickPositions":[92,108.25,124.5,140.75,157],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,113.18,116.49064643076923,119.80129286153847,123.1119392923077,126.42258572307692,129.73323215384616,133.04387858461538,136.3545250153846,139.66517144615383,142.97581787692306,146.2864643076923,149.59711073846154,152.90775716923076,{"y":156.2184036,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,113.18,115.08868639846155,116.99737279692309,118.90605919538461,120.81474559384615,122.7234319923077,124.63211839076924,126.54080478923076,128.4494911876923,130.35817758615383,132.26686398461538,134.1755503830769,136.08423678153846,{"y":137.99292318,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,113.18,112.68532634307692,112.19065268615385,111.69597902923077,111.2013053723077,110.70663171538462,110.21195805846153,109.71728440153846,109.22261074461538,108.7279370876923,108.23326343076923,107.73858977384614,107.24391611692307,{"y":106.74924245999999,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":95.04,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 66,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":93.851,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.336,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.815,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":105.448,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103.855,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":119.287,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":126.499,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":119.439,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.67,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.829,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 58,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":110.76,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":113.18,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€156.22Average Price Target€137.99Lowest Price Target€106.75
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
BMO Capital Analyst forecast on IT:1GILD
Evan Seigerman
BMO Capital
BMO Capital
€151.01
Buy
32.00%
Upside
Reiterated
08/06/26
Analysts Offer Insights on Healthcare Companies: Niagen Bioscience (NASDAQ: NAGE) and Gilead Sciences (NASDAQ: GILD)
J.P. Morgan Analyst forecast on IT:1GILD
Chris Schott
J.P. Morgan
J.P. Morgan
€138.86
Buy
21.38%
Upside
Reiterated
08/06/26
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (NASDAQ: GILD), Staar Surgical (NASDAQ: STAA) and Elanco Animal Health (NYSE: ELAN)
Maxim Group Analyst forecast on IT:1GILD
Michael Okunewitch
Maxim Group
Maxim Group
€143.2
Buy
25.18%
Upside
Reiterated
08/06/26
Gilead: Strong HIV and Oncology Growth Underpins Reiterated Buy Rating and Unchanged $165 Price Target
TD Cowen Analyst forecast on IT:1GILD
Tyler Van Buren
TD Cowen
TD Cowen
€138.86
Buy
21.38%
Upside
Assigned
08/05/26
Gilead Sciences: Strong Core Performance and Upgraded HIV Outlook Underpin Buy Rating and Earnings Power
Needham Analyst forecast on IT:1GILD
Joseph Stringer
Needham
Needham
€147.54
Buy
28.97%
Upside
Reiterated
08/05/26
Gilead Buy Rating Reaffirmed on Strong HIV-Driven Growth and Raised Revenue Outlook; $170 Price Target Maintained
Truist Financial Analyst forecast on IT:1GILD
Gregory Renza
Truist Financial
Truist Financial
€135.39→€130.18
Buy
13.80%
Upside
Reiterated
08/05/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Pediatrix Medical Group (NYSE: MD), Certara (NASDAQ: CERT) and Gilead Sciences (NASDAQ: GILD)
Wells Fargo Analyst forecast on IT:1GILD
Mohit Bansal
Wells Fargo
Wells Fargo
€143.2
Buy
25.18%
Upside
Assigned
08/05/26
Gilead Sciences (GILD) Gets a Buy from Wells Fargo
Morgan Stanley Analyst forecast on IT:1GILD
Terence Flynn
Morgan Stanley
Morgan Stanley
€143.2
Buy
25.18%
Upside
Reiterated
08/05/26
Gilead: Buy Rating Reaffirmed on Strong Fundamentals and HIV Franchise Momentum; $165 Price Target Maintained
Bank of America Securities Analyst forecast on IT:1GILD
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
€140.6
Buy
22.90%
Upside
Reiterated
08/05/26
Analysts Offer Insights on Healthcare Companies: InfuSystem Holdings (NYSE MKT: INFU), Arrowhead Pharmaceuticals (NASDAQ: ARWR) and Gilead Sciences (NASDAQ: GILD)
Evercore ISI Analyst forecast on IT:1GILD
Umer Raffat
Evercore ISI
Evercore ISI
―
Buy
―
Reiterated
08/05/26
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (NASDAQ: GILD), Ultragenyx Pharmaceutical (NASDAQ: RARE) and Beam Therapeutics (NASDAQ: BEAM)
Citi Analyst forecast on IT:1GILD
Geoff Meacham
Citi
Citi
€143.2
Buy
25.18%
Upside
Reiterated
08/04/26
Gilead Sciences (GILD) Gets a Buy from Citi
RBC Capital Analyst forecast on IT:1GILD
Brian Abrahams
RBC Capital
RBC Capital
€104.15→€106.75
Hold
-6.69%
Downside
Reiterated
08/04/26
RBC Capital Sticks to Its Hold Rating for Gilead Sciences (GILD)
Scotiabank Analyst forecast on IT:1GILD
Louise Chen
Scotiabank
Scotiabank
€153.61
Buy
34.28%
Upside
Reiterated
08/04/26
Gilead Sciences (GILD) Receives a Buy from Scotiabank
Cantor Fitzgerald Analyst forecast on IT:1GILD
Carter Gould
Cantor Fitzgerald
Cantor Fitzgerald
€134.52
Buy
17.59%
Upside
Reiterated
08/04/26
Cantor Fitzgerald Sticks to Its Buy Rating for Gilead Sciences (GILD)
Goldman Sachs Analyst forecast on IT:1GILD
Salveen Richter
Goldman Sachs
Goldman Sachs
€112.82
Hold
-1.38%
Downside
Reiterated
08/03/26
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (NASDAQ: GILD), Danaher (NYSE: DHR) and Henry Schein (NASDAQ: HSIC)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
BMO Capital Analyst forecast on IT:1GILD
Evan Seigerman
BMO Capital
BMO Capital
€151.01
Buy
32.00%
Upside
Reiterated
08/06/26
Analysts Offer Insights on Healthcare Companies: Niagen Bioscience (NASDAQ: NAGE) and Gilead Sciences (NASDAQ: GILD)
J.P. Morgan Analyst forecast on IT:1GILD
Chris Schott
J.P. Morgan
J.P. Morgan
€138.86
Buy
21.38%
Upside
Reiterated
08/06/26
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (NASDAQ: GILD), Staar Surgical (NASDAQ: STAA) and Elanco Animal Health (NYSE: ELAN)
Maxim Group Analyst forecast on IT:1GILD
Michael Okunewitch
Maxim Group
Maxim Group
€143.2
Buy
25.18%
Upside
Reiterated
08/06/26
Gilead: Strong HIV and Oncology Growth Underpins Reiterated Buy Rating and Unchanged $165 Price Target
TD Cowen Analyst forecast on IT:1GILD
Tyler Van Buren
TD Cowen
TD Cowen
€138.86
Buy
21.38%
Upside
Assigned
08/05/26
Gilead Sciences: Strong Core Performance and Upgraded HIV Outlook Underpin Buy Rating and Earnings Power
Needham Analyst forecast on IT:1GILD
Joseph Stringer
Needham
Needham
€147.54
Buy
28.97%
Upside
Reiterated
08/05/26
Gilead Buy Rating Reaffirmed on Strong HIV-Driven Growth and Raised Revenue Outlook; $170 Price Target Maintained
Truist Financial Analyst forecast on IT:1GILD
Gregory Renza
Truist Financial
Truist Financial
€135.39→€130.18
Buy
13.80%
Upside
Reiterated
08/05/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Pediatrix Medical Group (NYSE: MD), Certara (NASDAQ: CERT) and Gilead Sciences (NASDAQ: GILD)
Wells Fargo Analyst forecast on IT:1GILD
Mohit Bansal
Wells Fargo
Wells Fargo
€143.2
Buy
25.18%
Upside
Assigned
08/05/26
Gilead Sciences (GILD) Gets a Buy from Wells Fargo
Morgan Stanley Analyst forecast on IT:1GILD
Terence Flynn
Morgan Stanley
Morgan Stanley
€143.2
Buy
25.18%
Upside
Reiterated
08/05/26
Gilead: Buy Rating Reaffirmed on Strong Fundamentals and HIV Franchise Momentum; $165 Price Target Maintained
Bank of America Securities Analyst forecast on IT:1GILD
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
€140.6
Buy
22.90%
Upside
Reiterated
08/05/26
Analysts Offer Insights on Healthcare Companies: InfuSystem Holdings (NYSE MKT: INFU), Arrowhead Pharmaceuticals (NASDAQ: ARWR) and Gilead Sciences (NASDAQ: GILD)
Evercore ISI Analyst forecast on IT:1GILD
Umer Raffat
Evercore ISI
Evercore ISI
―
Buy
―
Reiterated
08/05/26
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (NASDAQ: GILD), Ultragenyx Pharmaceutical (NASDAQ: RARE) and Beam Therapeutics (NASDAQ: BEAM)
Citi Analyst forecast on IT:1GILD
Geoff Meacham
Citi
Citi
€143.2
Buy
25.18%
Upside
Reiterated
08/04/26
Gilead Sciences (GILD) Gets a Buy from Citi
RBC Capital Analyst forecast on IT:1GILD
Brian Abrahams
RBC Capital
RBC Capital
€104.15→€106.75
Hold
-6.69%
Downside
Reiterated
08/04/26
RBC Capital Sticks to Its Hold Rating for Gilead Sciences (GILD)
Scotiabank Analyst forecast on IT:1GILD
Louise Chen
Scotiabank
Scotiabank
€153.61
Buy
34.28%
Upside
Reiterated
08/04/26
Gilead Sciences (GILD) Receives a Buy from Scotiabank
Cantor Fitzgerald Analyst forecast on IT:1GILD
Carter Gould
Cantor Fitzgerald
Cantor Fitzgerald
€134.52
Buy
17.59%
Upside
Reiterated
08/04/26
Cantor Fitzgerald Sticks to Its Buy Rating for Gilead Sciences (GILD)
Goldman Sachs Analyst forecast on IT:1GILD
Salveen Richter
Goldman Sachs
Goldman Sachs
€112.82
Hold
-1.38%
Downside
Reiterated
08/03/26
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (NASDAQ: GILD), Danaher (NYSE: DHR) and Henry Schein (NASDAQ: HSIC)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
AMLXAmylyx Pharmaceuticals Inc
TNYATenaya Therapeutics
JBIOJade Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Gilead Sciences

3 Months
Courtney BreenBernstein
Success Rate
15/19 ratings generated profit
79%
Average Return
+6.25%
Copying Courtney Breen's trades and holding each position for 3 Months would result in 78.95% of your transactions generating a profit, with an average return of +6.25% per trade.
1 Year
Courtney BreenBernstein
Success Rate
17/19 ratings generated profit
89%
Average Return
+17.14%
Copying Courtney Breen's trades and holding each position for 1 Year would result in 89.47% of your transactions generating a profit, with an average return of +17.14% per trade.
2 Years
Salim SyedMizuho Securities
Success Rate
48/53 ratings generated profit
91%
Average Return
+34.26%
Copying Salim Syed's trades and holding each position for 2 Years would result in 90.57% of your transactions generating a profit, with an average return of +34.26% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

1GILD Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
0
0
0
0
0
Buy
48
41
58
53
50
Hold
13
12
13
13
10
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
61
53
71
66
60
In the current month, 1GILD has received 50 Buy Ratings, 10 Hold Ratings, and 0 Sell Ratings. 1GILD average Analyst price target in the past 3 months is 137.99.
Each month's total comprises the sum of three months' worth of ratings.

1GILD Financial Forecast

1GILD Earnings Forecast

Next quarter’s earnings estimate for 1GILD is €1.83 with a range of €1.22 to €2.00. The previous quarter’s EPS was -€5.86. 1GILD beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 46.32% of the time in the same period. In the last calendar year 1GILD has Performed in-line its overall industry.
Next quarter’s earnings estimate for 1GILD is €1.83 with a range of €1.22 to €2.00. The previous quarter’s EPS was -€5.86. 1GILD beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 46.32% of the time in the same period. In the last calendar year 1GILD has Performed in-line its overall industry.

1GILD Sales Forecast

Next quarter’s sales forecast for 1GILD is €6.75B with a range of €6.53B to €7.01B. The previous quarter’s sales results were €6.79B. 1GILD beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 31.16% of the time in the same period. In the last calendar year 1GILD has Performed in-line its overall industry.
Next quarter’s sales forecast for 1GILD is €6.75B with a range of €6.53B to €7.01B. The previous quarter’s sales results were €6.79B. 1GILD beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 31.16% of the time in the same period. In the last calendar year 1GILD has Performed in-line its overall industry.

1GILD Stock Forecast FAQ

What is IT:1GILD’s average 12-month price target, according to analysts?
Based on analyst ratings, Gilead Sciences’s 12-month average price target is 137.99.
    What is IT:1GILD’s upside potential, based on the analysts’ average price target?
    Gilead Sciences has 20.62% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Gilead Sciences a Buy, Sell or Hold?
          Gilead Sciences has a consensus rating of Strong Buy, which is based on 19 buy ratings, 4 hold ratings and 0 sell ratings.
            What is Gilead Sciences’s share price target?
            The average share price target for Gilead Sciences is 137.99. This is based on 23 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €156.22 ,and the lowest forecast is €106.75. The average share price target represents 20.62% Increase from the current price of €114.4.
              What do analysts say about Gilead Sciences?
              Gilead Sciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 23 Wall Streets Analysts.
                How can I buy shares of Gilead Sciences?
                To buy shares of IT:1GILD, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.